Drug Profile
TEV 90112
Alternative Names: TEV-90112Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in HIV-infections in Israel
- 01 Oct 2014 Phase-I clinical trials in HIV infections in Israel (unspecified route) prior to October 2014